Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Novo Nordisk Investigational Site
-
-
California
-
Berkeley, California, United States, 94704
- Novo Nordisk Investigational Site
-
Los Angeles, California, United States, 90027
- Novo Nordisk Investigational Site
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- Novo Nordisk Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Novo Nordisk Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Novo Nordisk Investigational Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Novo Nordisk Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Novo Nordisk Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Novo Nordisk Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Novo Nordisk Investigational Site
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Novo Nordisk Investigational Site
-
Newark, New Jersey, United States, 07112
- Novo Nordisk Investigational Site
-
-
New York
-
New York, New York, United States, 10029-6574
- Novo Nordisk Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7220
- Novo Nordisk Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Novo Nordisk Investigational Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Novo Nordisk Investigational Site
-
Philadelphia, Pennsylvania, United States, 19104
- Novo Nordisk Investigational Site
-
Philadelphia, Pennsylvania, United States, 19134-1095
- Novo Nordisk Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison with FEIBA on review of pain, joint mobility and circumference
Time Frame: after 1, 3, 6, and 9 hours of treatment, respectively
|
after 1, 3, 6, and 9 hours of treatment, respectively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Safety variables
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hematologic Diseases
- Blood Coagulation Disorders, Inherited
- Coagulation Protein Disorders
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Hemostatic Disorders
- Hemophilia A
- Hemophilia B
- Blood Coagulation Disorders
- Coagulants
- Anti-inhibitor coagulant complex
Other Study ID Numbers
Other Study ID Numbers
- F7HAEM-2068
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.